Fig. 7
From: Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation
α-DR3 exacerbates DSS-induced innate colitis through an ILC3-dependent manner. Littermate Rag1–/– (a–c, i–m), wild-type (d–h), Rag1–/–Rorcgfp/+, and Rag1–/–Rorcgfp/gfp mice (n–q) were fed with DSS in drinking water as indicated in a, d, i, and n. a–c 200 µg of DR3-Fc or control IgG were i.p. administered daily from day 3–6. d–q 2.5 µg (for wild-type mice) or 1 µg (for mice of Rag1–/– background) α-DR3 antibody or PBS was i.p. injected to mice on day −2, 0, and 2 post DSS treatment. a, d, i, n Percentages of weight change are shown. b, e, j, o Lengths of colons are shown. c, f, h, k, m, p Large intestinal LPLs were isolated on day 4 (except for on day 7 for c) post DSS treatment, and the expression of CD11b, Ly6G, Siglec-F, Lin, and RORγt were analyzed by flow cytometry. c, f, k, p Absolute numbers of neutrophils (CD11b+Ly6G+) and eosinophils (CD11b+SiglecF+) were analyzed by flow cytometry, calculated, and shown. h, m Absolute numbers of ILC3s (Lin–RORγt+) were analyzed by flow cytometry, calculated, and shown. g, l, q Paraffin-embedded colon sections were subjected to H&E staining, and histological scores are evaluated and shown. The data are means ± SEM. a–q The data are representative of at least two independent experiments. Source data are provided as a Source Data File
